Business
IceCure Launches Global #FreezeCancerNotYourLife Movement During Breast Cancer Awareness Month
ProSense® minimally invasive breast cancer procedure destroys tumors, freezing cancer in its tracks, empowering women to walk out of the procedure and back to
About this update from Icecure Medical Ltd.
[{"type":"text","content":"ProSense® minimally invasive breast cancer procedure destroys tumors, freezing cancer in its tracks, empowering women to walk out of the procedure and back to their lives\nCAESAREA, Israel, Oct. 26, 2022 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) (\"IceCure\" or the \"Company\"), developer of minimally-invasive cryoablation technology, the ProSense® System that destroys tumors by freezing, today reported on its Breast Cancer Awareness Month activities in clinics, training physicians, supporting patients, and exhibiting at industry conferences across the globe, including the launch of its campaign: #FreezeCancerNotYourLife\n\n \n \n\n \nProSense cryoablation provides women a minimally invasive in-office procedure for the treatment of breast cancer* with little to no downtime, minimal pain, only local anesthesia and no scarring. Moreover, patients and treating physicians report great cosmetic results. Women who have undergone the procedure report having no change to the shape and structure of their breast.\n\"We are working hard to bring our minimally invasive ProSense cryoablation solution to breast cancer patients across the globe so patients can freeze their cancer, not their life. Beyond destroying the tumor, we are supporting breast cancer patients' body image and sense of self. IceCure is innovating change in the way women's health issues are treated,\" stated Tlalit Bussi Tel-Tzure, IceCure's VP of Business Development. \"For Breast Cancer Awareness Month, our employees have been sharing their personal connections to breast cancer and saying what motivates them each day.\"\nSee the video here: LINK \n\"While we've been highly active across the board this month, we are most proud of having filed for marketing authorization with the FDA for ProSense with the Breakthrough Indication of early-stage low-risk breast cancer patients at high risk to surgery,\" stated IceCure CEO Eyal Shamir. \"Recently, ProSense has also been installed in several new sites including in Florida and South Carolina and numerous procedures have been performed in sites in Paris, Athens, Budapest, Bangkok and Singapore.\"\nIceCure's Breast Cancer Awareness Month activities include:\nPhysician Education & Training Webinars\nBreast Tumor Cryoablation for Breast Surgeons webinar hosted by Dr. Hania Bednarski of Serenity Surgery & Welln...